Will Green Cross challenge the domestic Lantus biosimilar market?
As Green Cross has made an attempt to avoid the patent of ‘Lantus,’ a Sanofi’s basal insulin, a background of the event has attracted interests.
The substance patent of Lantus will be expired on the 26th of February next year, but Green Cross has not aimed for the date to develop its biosimilar....
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
